TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04217460

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention for fluency difficulty
Description: Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention for fluency difficulty
Description: Children are required to speak materials they hear on recordings. The materials are not words, but contain sound sequences that occur in their language and English.
Study: NCT03574077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Instant Messaging (IM)
Description: Tailored automatic, fix- scheduled regular messages will be sent and counselors will interact with smokers in the intervention group through WhatsApp since initial contact and until 2-month after baseline. The interaction will follow the principle of Motivational Interviewing, which will focus on enabling change through the enhancement of intrinsic motivation and the exploration and resolution of ambivalence. Counsellors will identify discrepancies between participants' thought and their action, support their autonomy, be empathetic towards the participant, avoid confrontation, and adjust to resistance. Any smokers who do not use IM or refuse to receive IM messages will be contacted via SMS messages or telephone calls. For smokers who do not respond to regular messages, 3 additional prompt messages will be sent in the 1st month to initiate a conversation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARD advice
Description: AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AWARD advice
Description: AWARD will be delivered to smokers onsite and this includes: Ask about smoking history, Warn about the high risk, Advise to quit or reduce smoking as soon as possible, Refer smokers to smoking cessation services (with a SC service information card), and Do it again: to repeat the intervention; participants who fail to quit or relapse will be encouraged to quit again (and those who have quit smoking will be encouraged to prevent relapse) during telephone follow-ups. The whole process of AWARD can be delivered within 1 to 2 minutes.
Study: NCT04078568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg, with the maximum dose of 60g

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IVIG
Description: IVIG at a single dose of 2 g/kg, with the maximum dose of 60g

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Aspirin 30 mg/kg in oral per day (given in 3 divided doses), then 3 to 5 mg/kg per day when fever subsides for 3 days and C-reactive protein (CRP) is normal. Aspirin will be continued for at least 6 weeks after onset of illness.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Intravenous methylprednisolone 1.6 mg/kg per day (given in 2 divided doses, with the maximum dose 60mg of prednisolone ) for 3 days, then changed to oral prednisolone 2 mg/kg when fever subsides for 3 days. If CRP is normal, the oral dose will be reduced every 5 days from 2 mg/kg to 1 mg/kg to 0.5 mg/kg (tapered over 15 days). Then prednisolone will be discontinued.
Study: NCT04290663

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systematic RAI-treatment
Description: Administration of 3.7 GBq (100 mCi) or 1,1 GBq (30 mCi) of I131 at the choice of the investigator after rhTSH-stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision of RAI-treatment guided by a post-operative assessment
Description: The decision-making for the administration of an adapted RAI-treatment will be taken according to the following criteria:~* No RAI treatment if Tg/LT4 ≤1 ng/mL and rhTSH-sTg ≤10 ng/mL and normal diagnostic RAI-scintigraphy~* 1.1 GBq after rhTSH if Tg/LT4\>1 ng/mL or rhTSH-sTg\>10 ng/mL and normal diagnostic RAI-scintigraphy.~* 3.7 GBq after rhTSH if metastatic lymph-node(s) detected on diagnostic RAI-scintigraphy without distant metastasis~* 3.7 GBq after hormone withdrawal if distant metastasis detected on diagnostic RAI-scintigraphy or on the hybrid CT scan of the SPECT-CT acquisition
Study: NCT03707808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intratumoral injection of autologous CD1c (BDCA-1)+ myDC
Description: intratumoral injections plus intravenous administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intratumoral injection of ipilimumab and AS01b
Description: Intratumoral injection of ipilimumab and AS01b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of ipilimumab and AS01b
Description: Intratumoral injection of ipilimumab and AS01b

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV nivolumab
Description: Nivolumab administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV nivolumab
Description: Nivolumab administered intravenously
Study: NCT03337698

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
Study: NCT03574077

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NRT sampling
Description: One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NRT sampling
Description: One-week free nicotine replacement therapy (NRT) sampling (gum or patch) will be disseminated to participants who are interested to try after completing the baseline questionnaire. An NRT use card containing reminders of NRT use and potential side effects will be given. Counselors and research staff will also check the side effects of NRT use during WhatsApp interaction and telephone follow-ups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active referral
Description: SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active referral
Description: SC ambassadors will introduce various SC services in Hong Kong (using the SC service information card) and motivate smokers to use the SC services. Written consents will be obtained from smokers who are ready to book the service onsite for transfer of their contact telephone numbers to their chosen service providers. Our research staff will transfer the information to the service providers within a week since the enrollment. For smokers in Group A, our research staff will also assist them to re-book the appointments upon their request at follow-up. SC ambassadors will encourage smokers in Group A who are not ready to book SC service to make an early appointment and assist them at follow-up.
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab is administered by IV on Day 1 of each 21 day cycle or on Days 1 and 15 of each 28 day cycle.
Study: NCT03574077

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SMS messaging
Description: All smokers will receive fix-schedule general messages on SC through short message service (SMS) since their initial participation until 2-month after baseline. These messages include: (a) brief health warning, (b) benefit of quitting, (c) methods to quit and to cope with craving, and (d) SC services and their effectiveness. General SC messages will be sent twice per week in the 1st month and once per week in the 2nd month after joining this study.
Study: NCT03343743

Intervention type: OTHER
Group type: OTHER
Intervention: Oligomineral water
Description: Patients were instructed to drink at least 2 L/day of a hypotonic, oligomineral water low in sodium and minerals (fixed residue at 180°C \<200 mg/L) for at least 12 months
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.
Study: NCT00649077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam Tablets 15 mg
Description: 15mg, single dose fasting
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6958688
Description: Cycle 1:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle at increasing dosage.~Subsequent cycles:~RO6958688 is administered by IV infusion on Days 1, 8, and 15 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is administered by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel is administered by IV on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel is administered by IV on Day 1 of each 21 day cycle.
Study: NCT00649077

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mobic® Tablets 15 mg
Description: 15mg, single dose fasting
Study: NCT03045653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamoxifen Oral Product
Description: Tamoxifen 100 mg/d or high-dose Tamoxifen(100 mg/d ) plus chemotherapy
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-444
Description: CPI-444 is administered orally twice daily on Days 1- 21, of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed is administered by IV on Day 1 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin is administered by IV on day 1 of the first 4 or 6 cycles out of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is administered by IV on Days 1 and 8 of the first 4 or 6 cycles out of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linagliptin
Description: Linagliptin is administered orally once daily on Days 1 to 21 out of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab is administered for the management of cytokine-release syndrome in the RO6958688-containing arms.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Ipatasertib will be administered orally once a day on Days 1-21 of each 28-day cycle.
Study: NCT04106908

Intervention type: BIOLOGICAL
Intervention: Eqwilate
Description: Eqwilate® is a new generation, albumin-free, high-purity, double virus-inactivated, freezedried concentrate of VWF and FVIII
Study: NCT01724177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: 25 mg of Lenalidomide administered orally once daily
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered by IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered by IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered by IV on Day 1 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is administered by IV on Day 1 of each 21-day cycle.
Study: NCT00370591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate and fluticasone propionate
Study: NCT02692807

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgical procedures
Description: See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic surgical procedures
Description: See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Arthroscopic surgical procedures
Description: See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan is administered by IV on Day 1 and 8 of each 21-day cycle.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Radiotherapy up to 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Evolocumab is administered subcutaneously at a dose of 140 mg on Days 1 and 15 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiragolumab
Description: Tiragolumab is administered on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is administered on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab is administered on Day 1 of each 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL092
Description: XL092 is administered orally once a day on Day 1 to Day 21 of a 21 day cycle.
Study: NCT01781104

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RM-131
Description: Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo delivered subcutaneously once daily for 14 days.
Study: NCT01624480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
Study: NCT03337698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camonsertib
Description: Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camonsertib
Description: Camonsertib is administered orally on Days 1-3, Days 8-10 of a 21 day cycle.
Study: NCT03853031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LVEDA cm2 guided intraoperative fluid in TEE /Study Group
Description: Placement of Transoesophageal echocardiography probe in TEE group to measure Left ventricular end diastolic area cm2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CVP guided intraoperative fluid in CVP / Control group
Description: Ultrasound guided Internal Jugular Vein catheter placement in CVP group to measure CVP value cms H2O .
Study: NCT04254549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: 550 mg by mouth three times daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth three times daily for 14 days
Study: NCT03421340

Intervention type: DEVICE
Group type: OTHER
Intervention: DSC
Description: Stone removal without fluoroscopy using the SpyGlass device.

Intervention type: DEVICE
Group type: OTHER
Intervention: ERC
Description: Standard of care stone removal with fluoroscopy.
Study: NCT01624480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Armodafinil
Description: The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
Study: NCT02635919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mSMART
Description: A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
Study: NCT01986803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point.
Study: NCT03298945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miralax-Gatorade Prep
Description: 2-L split-dose Miralax-Gatorade bowel prep for colonoscopy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: 4-L split dose Golytely is the current standard prep at the VA
Study: NCT01820611

Intervention type: DEVICE
Intervention: Arcos Revision Stem System
Description: Revision Hip System
Study: NCT01986803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point.
Study: NCT04559477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static extension endurance exercise
Description: Static extension endurance exercise were performed, 10 repetitions with 10 sec hold of each of exercises Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks
Study: NCT04458857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fremanezumab
Description: Dose A or Dose B subcutaneous
Study: NCT04559477

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dynamic extension endurance exercise
Description: Dynamic extension endurance exercise with 10 repetitions of each of exercises which has been performed Heating pad:15 mins TENS: 15 mins~35 min/session, 3 sessions/week for 6 weeks
Study: NCT00424593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: every day (QD), by mouth (PO), 13 weeks